Bladder Cancer

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.

Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.

The approval of atezolizumab will change the treatment paradigm of bladder cancer overnight, says Robert Dreicer.

Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.

The FDA's breakthrough designation is meant to expedite the development of therapies that offer substantial benefits over existing options.

"Response rate and survival were similar to historical controls, and the primary endpoint was not met," said lead investigator Matthew Galsky.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.

Rick Bulifant shares his bladder cancer story.

CURE Magazine and the Bladder Cancer Advocacy Network (BCAN), whose mission is to advance research, provide information and support, and raise awareness of bladder cancer, have joined forces to battle the fifth most common type of cancer, which begins when the cells in the bladder's lining start to grow out of control.

Data from an ongoing trial showed that one fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor Keytruda.

Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.

In the right cancer, radiation and chemotherapy can make a powerful duo.

Urinary incontinence after a cancer diagnosis can be managed.

New treatments for bladder cancer may be nearing the finish line.

Editor Debu Tripathy, MD, highlights the need for new treatments needed for bladder cancer and other stories in CURE.

Advocating for yourself.

Minimally invasive technologies transform the landscape of cancer surgery.

Article outlines risk factors for bladder cancer.